

This article was downloaded by:

On: 30 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Spectroscopy Letters

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597299>

PMR Assay of Natural Products in Pharmaceuticals I: Assay of Noscapine in Tablets

Elsayed A. Aboutabl^a; M. M. A. Hassan^a

^a Department of Pharmacognosy and Pharmaceutical Chemistry, College of Pharmacy, Riyad University, Riyad, Saudi Arabia

To cite this Article Aboutabl, Elsayed A. and Hassan, M. M. A.(1979) 'PMR Assay of Natural Products in Pharmaceuticals I: Assay of Noscapine in Tablets', *Spectroscopy Letters*, 12: 3, 231 — 241

To link to this Article: DOI: 10.1080/00387017908069149

URL: <http://dx.doi.org/10.1080/00387017908069149>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

PMR ASSAY OF NATURAL PRODUCTS IN PHARMACEUTICALS I:
ASSAY OF NOSCAPINE IN TABLETS

Key Words: NMR analysis, Noscapine; NMR analysis, Narcotine, 1- α -Narcotine; NMR analysis, Tusscapine, Tuscapin.

Elsayed A. Aboutabl and M.M.A. Hassan
Department of Pharmacognosy and
Pharmaceutical Chemistry, College
of Pharmacy, Riyad University,
Riyad, Saudi Arabia


Abstract

A rapid and accurate PMR procedure is reported for the analysis of noscapine as a drug entity and in tablet dosage form. The method is precise with a standard deviation of $\pm 1.44\%$ and 1.12% in the alkaloid and tablets respectively. The results of synthetic mixtures and tablets are comparable to those obtained by B.P. 1973 and NF. XIII procedures. In addition, the PMR spectrum furnishes a specific means of identification of noscapine.

Introduction

Noscapine I $\left[1-\alpha-2\text{-methyl-8-methoxy-6-7-methylenedioxy-1-(6,7\text{-dimethoxy-3-pythalidyl)-1,2,3,4-tetrahydroisoquinoline}\right]$ is one of

the opium alkaloids and being nonaddictive, it is widely used as an antitussive in the treatment of unproductive cough. Due to its bronchodilating properties it is used to suppress the cough of bronchitis and for the relief of whooping cough in children (1).



Several approaches have been undertaken for the determination of I. A gravimetric method of determination based on precipitation with tetraphenyl boron has been described (2). Amperometric titration (3) and polarographic (4,5) methods were also reported. In plasma and urine, I has been determined by spectrofluorometry (6). A spectrophotometric method has been described (7) for the estimation of I based on measuring the absorbance of 0.1N HCl solution of the extracted base at 312 nm. This method is adopted by the B.P.C. 1973. A combination of this method with TLC has been described for the determination of I in opium (8). A method using the first derivative curve has also been reported (9). A quantitative

TLC technique was applied for the assay of I in drug mixtures (10). Non-aqueous titration is the method officially adopted by the B.P. 1973 (11) and NF. XIII (12).

By virtue of the relatively high dosage of noscapine (30 mg), the non-specificity of the methods previously described for its analysis and the characteristic resonance pattern of its PMR spectrum, it was deemed of interest to investigate a PMR assay of this alkaloid as a pure drug and in its tablet dosage form.

Experimental

Apparatus and chemicals - NMR spectrometer¹ was used. Standard Noscapine², commercial tablets³ of I, internal standard tert-butanol II², deuterated chloroform⁴ and ethanol-free chloroform were used.

All chemical shifts reported are in reference to tetramethylsilane at 0 ppm.

Preparation of ethanol-free chloroform (13) - The chloroform is shaken three times with small volume of concentrated sulphuric acid, thoroughly washed with water, dried over anhydrous calcium chloride and distilled.

1. Varian T-60A, 60MHz.

2. B.D.H. Chemicals, Poole, England.

3. Arab Pharmaceutical Manufacturers Co. Ltd., Sult., Jordan.

4. Koch-Light Laboratories Ltd., Colnbrook Bucks, England.

Preparation of I tablet sample solutions - Weigh and finely powder not less than 20 tablets. Weigh accurately a portion of the powder equivalent to about 100 mg of I, into a glass stoppered centrifuge tube. Add 4 ml. of ethanol-free chloroform containing the specified accurately weighed amount of II. Stopper and shake for 3 min. and then centrifuge. Transfer about 0.5 ml of the clear supernatant solution into a percision NMR spectrometer and obtain the spectrum, adjusting the spin rate to eliminate the spinning side-bands as much as possible. Integrate the peaks of interest (the nine protons of the three -OCH₃ groups of I appearing at 3.83, 4.00 and 4.05 ppm and the nine protons of the three -CH₃ groups of II appearing at 1.3 ppm as a singlet) at least three times and determine the average integrals.

The amount of I may then be calculated as follows:

$$\text{mg of I} = \frac{A_x}{A_a} \times \frac{413.43}{74.13} \times \text{mg II}$$

where:

A_x = Integral value of the signal representing I.

A_a = Integral value of the signal representing II.

413.43 = Molecular weight of I.

74.13 = Molecular weight of II.

Results and Discussion

The PMR spectrum of I shown in Fig. 1 displays characteristic signals, the chemical shifts of which are listed in Table I. The signals at 3.83, 4.00 and 4.05 ppm are ascribable to the nine pro-




Figure 1 - PMR spectrum of noscapine I and TMS, tetramethylsilane in deuterated chloroform.

Table I - Chemical Shifts of Noscapine in CDCl_3

Group	Position	Chemical Shift
$-\text{CH}_2-\text{CH}_2$	3,4	2.37 (m)
$\text{N}-\text{CH}_3$	2	2.50 (s)
$\text{O}-\text{CH}_3$	8	3.83 (s)
$\text{O}-\text{CH}_3$	6 of phthalidyl	4.00 (s)
$\text{O}-\text{CH}_3$	7 of phthalidyl	4.05 (s)
$-\text{CH}-$	1	4.37 (d)
$-\text{CH}_2-$	methylene dioxy	5.73 (s)
$-\text{CH}-$	3 of phthalidyl	6.10 (d)
$-\text{CH}-$	5	6.27 (s)
$-\text{CH}-$	4,5 of phthalidyl	6.93 (d)

(s) = singlet, (d) = doublet, (m) = multiplet.

tons of the three $-\text{OCH}_3$ groups of I. These nine protons were chosen for quantitative analysis, since integration of them gives the largest region for measurement.

tert-Butanol II is employed as an internal standard, since it exhibits (Fig. 2) a nine protons singlet at 1.3 ppm assigned to its




Figure 2 - PMR spectrum of noscapine I, tert-butanol II and TMS, tetramethylsilane in ethanol-free chloroform.

three methyl groups which is widely separated from those chosen for I thus allowing facile and accurate determination. The use of tert-butanol as an internal standard has been previously established (14).

Chloroform was chosen as a solvent, since compound I and II are freely soluble in it. Moreover, its proton signlet at 7.25 ppm does not interfere with the upfield protons of both compounds. Accordingly, the use of deuterated solvent is unnecessary. However, ethanol-free chloroform was used to avoid signal interference due to ethanol usually added as a stabilizer in the commercial product. A series of known standard I mixtures were prepared and assayed by this PMR technique and the results are summarized in Table II. The method is both accurate and precise, with a standard deviation of $\pm 1.44\%$. The accuracy of the determination is not significantly affected by the relative proportions of I to II. Applying this procedure to commercial tablets of I, the results are in good agreement with the declared dosage (Table III). The results are also comparable with those obtained using the official B.P. 1973 and NF. XIII procedure. There is no evidence of interference from excipients present.

The method has distinct advantages over other methods previously described, being rapid, accurate and specific. Moreover, the simultaneous detection of impurities in the sample can be achieved.

Acknowledgement

The authors are thankful to Mr. Khalid N.K. Lodhi of the Central laboratory, College of Pharmacy, Riyad University for running the PMR spectra.

Table II - Determination of Noscapine in Standard Mixtures by PMR.

Standard Mixture	tert-Butanol Internal Standard Added, mg	N o s c a p i n e		
		Added, mg	Found, mg	Recovery %
1	56.2	60	59.70	99.50
2	112.4	61	60.98	99.97
3	28.1	82	84.83	103.20
4	28.1	70	69.14	98.77
5	28.1	128	127.34	99.48
6	28.1	95	94.67	99.65
7	28.1	154	151.82	98.58
8	28.1	146	146	100.41
9	28.1	184	184.02	100.01
			Average	99.95
			SD	± 1.44

Table III - Determination of Noscapine Tablets by PMR

Sample	tert-Butanol Internal Standard Added, mg	N o s c a p i n e		
		Declared, mg per 4 tablets	Found, mg per 4 tablets	Recovery % w/w
1	22.48	100	97.16	97.16
2	22.48	100	97.85	97.85
3	33.72	100	96.32	96.32
4	33.72	100	97.86	97.86
5	22.48	100	96.32	96.32
6	22.48	100	94.80	94.80
7	22.48	100	94.80	94.80
8	22.48	100	97.06	97.06
9	22.48	100	96.00	96.00
10	22.48	100	95.52	95.52
			Average	96.37
			SD	± 1.12

REFERENCES

1. British Pharmaceutical Codex, The Pharmaceutical Press, London, 1973, p. 331.
2. Schultz, O.E., and G. Mayer, Deut. Apotheker Ztg, 91, 358 (1952).
3. Higuchi, T. and Brochmann - Hanssen, E., "Pharmaceutical Analysis", Interscience Publishers, (New York), 1961, p. 405.
4. Kirkpatrick, H.F.W., Quart. J. Pharm. and Pharmacol., 18, 245 (1945).
5. Pech, J., Collection Czechoslov. Chem. Communs., 6, 190 (1934).
6. Vedso, S., Acta Pharmac. tox., 18, 119 and 157 (1961).
7. Berman, E. and H.N. Wright, Arch. Ind. Hyg. and Occupational Med., 8, 518 (1953).
8. Fairbairn, J.W., and El-Masry, S., J. Pharm. Pharmac. 19, Supp., 93 S (1967).
9. Wahbi, A.M., Analyst Chim., 70 (1), 57 (1974).
10. Schlemme, E.W., J. Chromat., 63 (1), 121 (1971).
11. British Pharmacopoeia, Her Majesty's Stationery Office, London, 1973, p. 325.
12. National Formulary XIII, American Pharmaceutical Association, Washington DC, 1970.

13. Vogel, A.I., "A Text-book of Practical Organic Chemistry", 3rd Ed., Longman (London), 1970, p. 176.
14. Goldwitz, B.A. and Turczan, J.W., J. Pharm. Sci., 62, 1, 115 (1973).

Received 1-16-79

Accepted 2-05-79